Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
End-stage Renal Disease
About this trial
This is an interventional treatment trial for End-stage Renal Disease focused on measuring end-stage renal disease, hemodialysis, volume control, ultrafiltration, inflammation, cardiovascular disease, left ventricular hypertrophy, dietary salt restriction
Eligibility Criteria
Inclusion Criteria: aged between 18-70 years old on maintenance bicarbonate hemodialysis scheduled thrice weekly, at least 12 hours/week willingness to participate in the study with a written informed consent. Exclusion Criteria: to be scheduled for living donor renal transplantation to have serious life-limiting co-morbid situations; namely active malignancy, active infection, end-stage cardiac, pulmonary, or hepatic disease; pregnancy or lactating
Sites / Locations
- Ege University School of Medicine Division of Nephrology
- Adana Numune Research and Education Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Other
strict volume control policy
antihypertensive drugs administration
strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.